Suven Pharmaceuticals has acquired 56% equity share capital of NJ Bio, Inc., at an aggregate consideration of $64.4 million, which includes $15 million of primary equity infusion into the NJ Bio. Therefore, the acquisition of 56% equity share capital of NJ Bio by the company has been completed on December 20, 2024.
Suven Pharmaceuticals is India’s leading technology-focused CDMO, offering integrated solutions in custom synthesis, process R&D, and manufacturing for global innovators.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1660.80 |
| Dr. Reddys Lab | 1221.60 |
| Cipla | 1235.35 |
| Zydus Lifesciences | 930.00 |
| Lupin | 2314.00 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: